CBD Side Effects: A Comprehensive Safety Guide

One of the most important things to communicate about CBD's safety is that it is, by any reasonable pharmacological standard, a remarkably safe compound. This is not a commercial claim but the conclusion of one of the most thorough independent reviews of a psychoactive substance ever conducted: the World Health Organization's Critical Review of Cannabidiol (CBD), published in November 2018 by the Expert Committee on Drug Dependence (ECDD). The review assessed all available preclinical and clinical evidence and concluded: "CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as a result of drug-drug interactions between CBD and patients' existing medications... to date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD."

This does not mean CBD is without adverse effects — it is not. But understanding the actual side effect profile — which adverse effects occur, at what doses, and in which populations — allows for rational, informed use rather than either dismissive overconfidence or unwarranted alarm. The vast majority of CBD's side effects are dose-dependent, mild, and reversible. The more serious concerns are primarily pharmacokinetic — relating to how CBD interacts with other medications rather than its direct toxicity.

At the doses used by most consumers (10–100 mg/day), CBD's reported side effects are generally mild and transient. The most commonly reported in clinical studies and real-world surveys are:

• Dry mouth (xerostomia): The most frequently reported side effect, occurring in approximately 10–15% of users. CBD and other cannabinoids inhibit saliva secretion by acting on cannabinoid receptors in the submandibular glands. It is uncomfortable but harmless. Staying well-hydrated and chewing sugar-free gum can mitigate it.
• Drowsiness/fatigue: Reported by approximately 5–10% of users, usually at higher doses. This is dose-dependent and often dose-limiting for daytime use. For evening/sleep use, this is typically the desired effect rather than a side effect. It can indicate the dose is above the user's optimal level.
• Reduced appetite: Some users report mild appetite suppression, consistent with CBD's 5-HT1A and TRPV1 mechanisms. This contrasts with THC's appetite-stimulating effects and is generally mild.
• Diarrhoea/GI upset: The most common GI complaint, particularly at higher doses. In the Epidiolex clinical trials (which used doses up to 20 mg/kg/day — far above consumer levels), diarrhoea was reported in up to 20% of participants. At consumer doses, GI disturbance is less common but real, and often related to the carrier oil (MCT oil can cause GI issues in some individuals at high doses) rather than CBD itself.
• Changes in weight: Reported in longer-term clinical studies, likely secondary to the appetite and GI effects above, and not consistently in any single direction.

The single most important safety consideration for CBD — far more clinically significant than its direct side effects — is its interaction with the cytochrome P450 (CYP450) enzyme system. CYP450 enzymes are a family of liver enzymes responsible for metabolising approximately 60% of all prescribed medications. By inhibiting key CYP450 enzymes, CBD can alter the blood levels of a wide range of drugs — either raising them (if CBD inhibits the enzyme that normally breaks them down) or lowering them (in more complex interactions involving CYP enzyme induction).

CBD is a potent inhibitor of CYP3A4 and CYP2C19 — the two most clinically important CYP enzymes in human drug metabolism. CYP3A4 metabolises approximately 50% of all drugs in clinical use, including statins, calcium channel blockers, antihistamines, immunosuppressants, many antiepileptic drugs, several SSRIs and SNRIs, and benzodiazepines. CYP2C19 metabolises proton pump inhibitors (omeprazole, lansoprazole), clopidogrel (an antiplatelet drug with the unusual property that CYP2C19 inhibition reduces its efficacy by blocking its activation to the active form), several antiepileptics, and certain SSRIs.

In practice, this means that if you take CBD alongside a medication that relies on CYP3A4 or CYP2C19 for its metabolism, the medication may accumulate to higher blood levels than expected — potentially producing toxicity — or, in the case of prodrugs like clopidogrel, fail to be adequately activated. The "grapefruit warning" on many medication leaflets is a useful analogy: grapefruit juice inhibits the same CYP3A4 enzyme, which is why it is contraindicated with many drugs. CBD's inhibitory potency is broadly comparable to grapefruit juice at typical consumer doses and potentially stronger at higher doses.

Certain drug categories deserve particular attention for CBD interactions:

• Warfarin and other anticoagulants: This is among the most clinically significant interactions. CBD inhibits CYP2C9 — the enzyme primarily responsible for warfarin metabolism — potentially raising warfarin blood levels and increasing bleeding risk. Several case reports of elevated INR (coagulation measure) in warfarin patients who started CBD have been published. Anyone on warfarin or other anticoagulants (rivaroxaban, apixaban) should not use CBD without specialist medical supervision and regular coagulation monitoring.
• Antiepileptic drugs: Paradoxically, given that CBD (Epidiolex) is itself an antiepileptic, CBD interacts with many other antiepileptic drugs. Clobazam levels are elevated by CBD via CYP3A4 inhibition — the Epidiolex trials required dose reductions of clobazam in many participants. Valproate appears to increase the risk of CBD-associated liver enzyme elevations in combination.
• Immunosuppressants: Cyclosporine, tacrolimus, and sirolimus — used after organ transplantation — are all CYP3A4 substrates with narrow therapeutic windows. Small changes in plasma levels can cause either rejection or toxicity. CBD is contraindicated alongside these drugs without transplant specialist oversight.
• Statins: Simvastatin and lovastatin (but not pravastatin or rosuvastatin, which are metabolised differently) are CYP3A4 substrates. CBD may raise statin levels, increasing myopathy risk. If on a CYP3A4-metabolised statin and using CBD, discussing a switch to pravastatin or rosuvastatin with your GP is a reasonable precaution.

Elevated liver enzymes (alanine aminotransferase, ALT, and aspartate aminotransferase, AST) were observed in some participants in the Epidiolex clinical trials, particularly those receiving the highest doses (20 mg/kg/day) or those co-prescribed valproate. This finding prompted careful scrutiny of CBD's hepatotoxic potential. The FDA's prescribing information for Epidiolex includes a warning about elevated transaminases and recommends regular liver function monitoring.

In the context of consumer CBD use, these trial findings require careful interpretation. The doses in question are 5–10 times higher than most consumers ever take. A review of the Epidiolex data found that liver enzyme elevations occurred in approximately 5–10% of participants at high doses, were generally reversible on dose reduction or discontinuation, and were more common in patients also taking valproate. Real-world post-market data on consumer CBD at doses below 300 mg/day has not revealed a significant liver safety signal.

As a precaution, if you plan to take high-dose CBD (above 100 mg/day) long-term, periodic liver function testing (LFTs) every six months is a reasonable and inexpensive safeguard. Most GPs will provide this on request. If you are already taking any hepatotoxic medication (methotrexate, isoniazid, amiodarone), discuss CBD use with your doctor before starting.

While CBD is safe for the vast majority of healthy adults, specific populations warrant particular caution. Pregnant and breastfeeding women should avoid CBD. While there are no well-controlled human studies demonstrating harm (for obvious ethical reasons), preclinical evidence shows CBD crosses the placental barrier and is present in breast milk. The FDA, MHRA, and NHS all advise against CBD use in pregnancy and lactation. This is a precautionary recommendation given the critical importance of this developmental period.

Children and adolescents should not use consumer CBD without specific medical supervision. The adolescent endocannabinoid system is actively developing, and while Epidiolex is licensed and used in children for severe epilepsy under specialist care, the use of consumer CBD supplements in children for non-medical reasons lacks evidence and introduces unnecessary risk. People with pre-existing liver disease should consult their hepatologist before using CBD at any dose, given the liver enzyme findings at high doses. People on multiple prescription medications — particularly those mentioned above — should have their CBD use reviewed by their prescriber before starting. A simple medication review conversation with your GP is the appropriate first step.

Alcohol and CBD interact in ways that are relevant to many users. Both CBD and alcohol have CNS-depressant properties, and their combination can produce additive sedation — more than either compound alone. A small human crossover study found that 200 mg of CBD combined with alcohol produced significantly lower blood alcohol levels compared to alcohol alone, but with greater impairment on some motor tasks — suggesting that while CBD may reduce alcohol absorption, it does not reduce impairment and may in some measures worsen it.

CBD has attracted interest as a potential harm-reduction tool for alcohol use disorder. Preclinical evidence shows CBD reduces alcohol self-administration in rodents, reduces alcohol-related neuroinflammation and neurodegeneration, and may reduce relapse-associated craving cues. A small human pilot trial found CBD reduced craving and anxiety in abstinent alcoholics in the clinical setting, though large-scale RCT evidence is not yet available. For those using CBD alongside alcohol socially, the key practical message is to reduce alcohol quantity and be aware that combination may produce greater sedation than expected — never drive after combining CBD and alcohol.

Most CBD side effects respond well to simple dose reduction. If you experience significant drowsiness, GI upset, or mood changes after starting CBD, reduce your daily dose by 50% and hold for one week before reassessing. If symptoms persist at reduced dose, try a different product format (switching from MCT-carrier oil to a hemp-seed-oil-based product resolves GI issues in some users, as MCT oil itself causes diarrhoea in susceptible individuals at high doses).

More significant concerns — particularly changes in the effects of other medications, new bruising or bleeding in anticoagulated patients, or unexpected mood changes — warrant contact with your GP. Take your CBD product to the appointment so the doctor can see the exact formulation, concentration, and ingredients — this information is essential for assessing potential interactions. When reporting CBD use to healthcare professionals, be specific: "I take 50 mg of full-spectrum CBD oil sublingually twice daily" is far more useful than "I take some CBD." Clear communication enables clear clinical decision-making.